Photoacoustic Tomography: Ultrasonically Breaking Through the Optical Diffusion Limit

Article

Photoacoustic tomography (PAT), a new imaging technique that relies on light and sound, provides in vivo multiscale nonionizing functional and molecular imaging without the radiation emitted by x-rays and CT scans, explained Lihong V. Wang, PhD, who led the team of developers at Washington University in St. Louis.

A wealth of data presented in posters, symposia, panel discussions, and plenary sessions at the 2012 meeting of the American Association for Cancer Research truly reflected this year’s theme, “Accelerating Science: Concept to Clinic.” The following is the first of a series of summaries of some of these presentations.

Photoacoustic tomography (PAT), a new imaging technique that relies on light and sound, provides in vivo multiscale nonionizing functional and molecular imaging without the radiation emitted by x-rays and CT scans, explained Lihong V. Wang, PhD, who led the team of developers at Washington University in St. Louis.

Lihong V. Wang, PhD

“PAT is the only modality capable of imaging across the length scales of organelles, cells, tissues, and organs with consistent contrast,” said Dr. Wang. The technique “has the potential to empower multiscale systems biology and accelerate translation from microscopic laboratory discoveries to macroscopic clinical practice.”

Dr. Wang said PAT may also hold the key to the earliest detection of cancer by in vivo label-free quantification of hypermetabolism, which he called “the quintessential hallmark of cancer.”

Dr. Wang is working with physicians at Washington University to evaluate PAT for use in identifying the sentinel lymph nodes for breast cancer staging (which may eliminate the need for surgical lymph node biopsies); monitoring early response to chemotherapy; imaging melanomas; and imaging the gastrointestinal tract.

“This technology is potentially a game changer, both in how we monitor cancer and in how soon we know it is there,” said Dr. Wang.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Related Content